Formulation Development
NovaCina Expands Perth Facility to Offer Clinical Supplies Service for Global Market
NovaCina recently announced the expansion of its facility in Perth, Australia with the introduction of a high-tech SA25 GMP filling line to assist customers with small-batch…
Transgene Provides Update on Phase 2 Trial of Therapeutic Cancer Vaccine in Recurrent or Metastatic HPV16-Positive Cervical & Anogenital Cancers
Transgene recently announced its randomized Phase 2 study to evaluate TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic HPV16-positive…
Inventiva Announces Financing to Advance NATiV3 Phase 3 MASH Study
Inventiva recently announced financing of immediately €94.1 million and up to €348 million, subject to satisfaction of specified conditions, to fund the completion of the…
Ardena Signs Agreement to Expand US Footprint With Acquisition of Advanced Drug Product Manufacturing Facility
Ardena recently announced it has signed a definitive agreement to acquire Catalent’s state-of-the-art facility in Somerset, NJ. This acquisition will significantly enhance Ardena’s capabilities in downstream…
Honeywell Technology to Power DevPro Biopharma’s Next-Generation Low-Emission Respiratory Inhaler
Honeywell recently announced a long-term supply agreement with DevPro Biopharma to develop a respiratory inhaler that enhances the well-being of patients while reducing carbon emissions associated…
MitoRx Therapeutics Announces Publication Showing Mitochondrial Sulfide Donor AP39 Significantly Alleviates Obesity
MitoRx Therapeutics recently announced a publication in Elsevier’s prestigious biomedical sciences journal Pharmacological Research. The work led by collaborators at Jagiellonian University Medical College showed…
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Trial With a microRNA-Targeted Technology
TransCode Therapeutics, Inc. recently announced it has dosed all patients in the first cohort of its Phase 1a dose-escalation clinical trial. The therapeutic candidate being…
Nanoscope Announces Plans to Submit BLA for Retinitis Pigmentosa Treatment
Nanoscope Therapeutics Inc. recently announced a productive FDA meeting for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP). Based on the regulatory…
Achieve Life Sciences Announces Completion of Enrollment in Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting
Achieve Life Sciences, Inc. recently announced an update on the ORCA-OL clinical trial, evaluating long-term exposure of the novel 3 mg cytisinicline treatment dosing regimen…
Palisade Bio Cleared to Commence Phase 1 Clinical Study for Ulcerative Colitis Treatment
Palisade Bio, Inc. recently announced it has received a No Objection Letter from Health Canada for its Phase 1 human clinical study for PALI-2108 for…
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
Can-Fite BioPharma Ltd. recently announced the its oncology drug candidate, Namodenoson, has been granted Orphan Drug Designation by the US FDA for the indication of…
Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer
Panavance Therapeutics Inc. recently announced the presentation of interim data from its Phase 1 clinical study evaluating misetionamide (GP-2250) in combination with gemcitabine at the 2024…
BrainDos Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution in Preclinical Study
MetP Pharma AG, leveraging the proprietary nose-to-brain drug delivery technology BrainDos in internal and external product development and manufacturing programs, recently announced preclinical data showing…
Sonnet BioTherapeutics Enters Licensing Agreement With Alkem Laboratories
Sonnet BioTherapeutics Holdings, Inc. recently announced it has entered into a licensing agreement with Alkem Laboratories Limited for the research, development, manufacturing, marketing, and commercialization…
Syneos Health Appoints Costa Panagos as Chief Executive Officer
Syneos Health recently announced the appointment of Costa Panagos as CEO and a member of the company’s Board of Directors, effective immediately. Panagos succeeds….
HBC Immunology Completes In Vivo Drug Lead Studies for Prostrate Cancer Treatment
HBC Immunology (HBCI) recently announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel oral formulation…
Qinotto & Lilly Enter Research Collaboration & License Agreement
Qinotto, Inc. recently announced it has entered a research collaboration and license agreement with Eli Lilly and Company (Lilly) to discover next-generation antibody-based vehicles for…
Simtra BioPharma Solutions Expands Capabilities With $14M Investment in ADC Conjugation & Purification Clinical Suite
Simtra BioPharma Solutions recently announced a $14-million investment to expand its clinical-scale conjugation and purification capabilities for Antibody-Drug Conjugates (ADCs). Set to be operational by…
Mestag Therapeutics Announces License & Research Collaboration With MSD
Mestag Therapeutics recently announced it has entered into a license and collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, NJ) to identify…
Avalo Announces First Patient Dosed in Phase 2 Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Avalo Therapeutics, Inc. recently announced the first patient has been dosed in its Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS). AVTX-009 is…
